for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Westlaw News

AbbVie hit with antitrust lawsuit over Humira 'patent thicket'

AbbVie Inc used a dense web of 100-plus patents to insulate its blockbuster drug Humira from U.S. competition while cutting deals with rivals that delayed the release of cheaper biosimilar versions, according to a proposed antitrust class action lawsuit.

The lawsuit, filed on Monday in Chicago federal court, accused AbbVie’s of using a so-called “patent thicket” to maintain a monopoly over the $20-billion-a-year drug, which is used to treat arthritis and other diseases and sells in the United States at ever-increasing prices.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2FnCOrs

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up